963-39-3
963-39-3
Chemical Structure
Demoxepam
- CAS 番号: 963-39-3
- Formula:C15H11ClN2O2
- Molecular Weight:286.71
IUPAC Name: 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine 4-oxide
InChIKey: GGRWZBVSUZZMKS-UHFFFAOYSA-N
SMILES: O=C1NC2=CC=C(Cl)C=C2C(C3=CC=CC=C3)=[N+]([O-])C1
Biological Activity: Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [3H]tryptophan binding to rat hepatic nuclei[1][2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Demoxepam | 99.5% | Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [3H]tryptophan binding to rat hepatic nuclei. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Demoxepam (Standard) | ≥98% | Demoxepam (Standard) is the analytical standard of Demoxepam. This product is intended for research and analytical applications. Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [3H]tryptophan binding to rat hepatic nuclei. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulazepam | 99.53% | Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Desalkylflurazepam (Standard) | ≥98% | N-Desalkylflurazepam (Standard) is the analytical standard of N-Desalkylflurazepam. This product is intended for research and analytical applications. N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ro5-3335 (Standard) | ≥98% | Ro5-3335 (Standard) is the analytical standard of Ro5-3335 (HY-108470). This product is intended for research and analytical applications. Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7-Aminoclonazepam | 99.17% | 7-Aminoclonazepam is a major metabolite of Clonazepam that can be for the assessment of Clonazepam use. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7-Aminoclonazepam-13C6 | 7-Aminoclonazepam-13C6 is a deuterated labeled 7-Aminoclonazepam. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Methylnordiazepam | 99.4% | 3-Methylnordiazepam (RO-5-2751) is a benzodiazepine and shows anticonvulsant activity in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Hydroxy desalkylgidazepam | 3-Hydroxy desalkylgidazepam (compound 2) is the active metabolite of Gidazepam (HY-U00315) and Desalkylgidazepam (HY-W634748). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deschlorodemethyldiazepam | 99.80% | Deschlorodemethyldiazepam is a benzodiazepines compound. Deschlorodemethyldiazepam can be hydroxylated in vitro by liver microsomal enzymes obtained from rats or mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Thionordiazepam | 98.18% | Thionordiazepam is a benzodiazepine compound and serves as an analytical reference standard for benzodiazepine-related psychoactive substances. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Desalkylgidazepam | Desalkylgidazepam (Bromonordiazepam) is the major active metabolite of Gidazepam (HY-U00315) and a benzodiazepine agent. Desalkylgidazepam activates GABAA receptors, binds to the benzodiazepine site, enhances GABA-mediated inhibitory neurotransmission, and potentiates GABA-induced chloride ion influx through positive allosteric modulation at α1β2γ2 receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moustapha Ouédraogo, et al. In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug Chem Toxicol. 2009;32(4):417-23. [Content Brief]
- [2]. Gregory G Sarris, et al. Demoxepam Derivatization and GC-MS Analysis Produces Erroneous Nordiazepam and Oxazepam Results. J Anal Toxicol. 2019 Jun 1;43(5):406-410. [Content Brief]
- [3]. Sidransky, H., et al., (1992). Inhibitory effect of demoxepam on tryptophan binding to rat hepatic nuclei. Biochemical medicine and metabolic biology, 47(3), 270–273. [Content Brief]
